FindMyKOL
Clinical trialNCT00712582CompletedPhase 2Interventional

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

NCT00712582 is a phase 2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Etoposide and Rituximab in Non-Hodgkin's Lymphoma. The registry lists an enrollment of 96 participants at 1 site in 1 country. The registry lists a start date of 1 Jul 2008 and a primary completion date of 12 Mar 2021. One of its registered investigators has a FindMyKOL profile.

SponsorMemorial Sloan Kettering Cancer Center →Enrollment96Non-Hodgkin's Lymphoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00712582
FieldValue
Registry IDNCT00712582
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorMemorial Sloan Kettering Cancer Center
Enrollment96
Registered sites1
Countries1
ConditionsNon-Hodgkin's Lymphoma
DrugsEtoposide and Rituximab
Start1 Jul 2008
Primary completion12 Mar 2021
Study completion12 Mar 2021
Last update posted21 Jun 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks. Each three weeks is a cycle. Some factors predict that you may not be cured with R-CHOP-21. The most common ones are: * Stage - how much DLBCL, PMBL, or FL3B you have * LDH - a blood chemistry marker; and * Whether you can do your normal daily activities. (performance status) We think that the best way to cure more patients with poor risk factors is to add new treatment to R-CHOP. You will get different chemotherapy after 4 cycles. This type of treatment is called risk-adapted therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Memorial Sloan Kettering Cancer Center

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EtoposideRituximab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00712582

Each answer restates registry values shown on this page.

What is NCT00712582?

NCT00712582 is a phase 2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Etoposide and Rituximab in Non-Hodgkin's Lymphoma.

Who leads NCT00712582?

The registry names Andrew Zelenetz, MD, PhD (principal investigator, Memorial Sloan Kettering Cancer Center) as the overall official.

Where does NCT00712582 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00712582 study?

The registered drug and biological interventions are Etoposide and Rituximab.

When did NCT00712582 end?

The registry lists a primary completion date of 12 Mar 2021 and a study completion date of 12 Mar 2021. The sponsor last updated the record on 21 Jun 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.